Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review

Author/s: 
Mackey, K., Arkhipova-Jenkins, I., Armstrong, C., Gean, E., Anderson, J., Paynter, R. A., Helfand, M.
Date Added: 
November 12, 2022
Journal/Publication: 
Agency for Healthcare Research and Quality
Publisher: 
US Department of Health and Human Services
Publication Date: 
March 15, 2021
Issue: 
21-EHC016
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
10.23970/AHRQEPCCOVIDIMMUNITY
PMID (1): 
33784032

RPR Commentary

Infection with the SARS-CoV-2 virus (COVID-19) induces substantial (around 90%) protection from reinfection for at least 6 months and probably longer. James W. Mold, MD, MPH

Abstract

The aims of this rapid systematic review are to synthesize evidence on the prevalence, levels, and durability of the antibody response to SARS-CoV-2 infection among adults and how antibodies correlate with protective immunity. Given the rapidly evolving evidence within this field, the Agency for Healthcare Research and Quality’s Evidence-based Practice Center (AHRQ EPC) Program will maintain this report as a living review with planned ongoing literature surveillance and critical appraisal. We will provide regular report updates as additional evidence becomes available, modifying the scope of the review as new directions in SARS-CoV-2 immunity research emerge. This review was conducted in coordination with the American College of Physicians (ACP) as part of AHRQ’s standing work to provide health professional organizations and systems with evidence reviews to support the development of clinical guidance for their clinician members.

Text Availability

Free full text